Spectranetics Corp. (The)
SPNC
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- Address
- IPO Date
- Jan 21, 1992
- CIK
- 0000789132
- Similar Companies
- Business
- Spectranetics Corp. (The) develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive cardiovascular procedures, including vascular intervention and lead management solutions. The company's core products encompass laser and aspiration catheters, such as the Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme support catheters; coronary intervention devices including the ELCA excimer laser ablation catheters and AngioSculpt scoring balloon catheters; QuickCat aspiration catheters for thrombus management; the Stellarex drug-coated balloon platform for peripheral arterial disease; and lead management tools comprising excimer laser sheaths, non-laser mechanical sheaths, cardiac lead accessories, and Bridge occlusion balloon catheters. These offerings also include excimer laser systems for atherectomy, crossing, preparation, and treatment of arterial blockages in the legs and heart, as well as pacemaker and defibrillator lead removal. Founded in 1984 and headquartered in Colorado Springs, Colorado, the company operates as a subsidiary of Philips Holding USA Inc. following its acquisition by Royal Philips on August 9, 2017, for approximately $2.2 billion, which integrated Spectranetics into Philips' Image-Guided Therapy business group to expand therapy device capabilities. Products are sold directly and through distributors in the United States, Canada, Europe, the Middle East, Asia Pacific including Japan and China, Russia, Latin America, and Puerto Rico. Spectranetics targets healthcare providers treating coronary and peripheral artery disease, chronic total occlusions, and cardiac implanted electrical device infections. No major acquisitions, partnerships, funding rounds, product launches, or strategic shifts have been reported for Spectranetics in the last 1-2 years; the entity continues to leverage its product portfolio within Philips' broader cardiovascular and image-guided therapy segments.